NASDAQ:MEDS - Trxade Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.33
  • Forecasted Upside: 158.56 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.77
▲ +0.01 (0.21%)
1 month | 3 months | 12 months
Get New Trxade Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.33
▲ +158.56% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Trxade Group in the last 3 months. The average price target is $12.33, with a high forecast of $15.00 and a low forecast of $10.00. The average price target represents a 158.56% upside from the last price of $4.77.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Trxade Group.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021Colliers SecuritiesReiterated RatingBuy$10.00High
i
2/26/2021Maxim GroupInitiated CoverageBuyHigh
i
12/3/2020National SecuritiesInitiated CoverageBuy$15.00High
i
6/10/2020Taglich BrothersReiterated RatingSpeculative BuyHigh
i
Rating by H. Halpern at Taglich Brothers
4/30/2020Dougherty & CoReiterated RatingBuy$12.00Low
i
Rating by Eugene Mannheimer at Dougherty & Co
(Data available from 4/19/2016 forward)
Trxade Group logo
Trxade Group, Inc., together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.com, a web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, an application, which offers product information. The company also operates a retail specialty pharmacy; Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; and Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics. In addition, it operates Trxade Prime, which allows pharmacy members on the Trxade platform to process, consolidate, and ship purchase orders that are placed directly with Trxade suppliers; Bonum Health Hub, a virtual examination room; Bonum+, a B2B platform to purchase COVID-19 risk assessment and personal protective equipment tools; and MedCheks, a healthcare platform that lets patients consolidate and control their health data via a digital Health Passport and allows them to share their health profile, tests, and vaccination. The company is based in Land O'Lakes, Florida.
Read More

Today's Range

Now: $4.77
$4.60
$4.90

50 Day Range

MA: $5.91
$4.76
$7.15

52 Week Range

Now: $4.77
$4.02
$8.25

Volume

54,700 shs

Average Volume

93,907 shs

Market Capitalization

$38.60 million

P/E Ratio

159.00

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Trxade Group?

The following Wall Street analysts have issued reports on Trxade Group in the last year: Colliers Securities, Dougherty & Co, Maxim Group, National Securities, Taglich Brothers, and Zacks Investment Research.
View the latest analyst ratings for MEDS.

What is the current price target for Trxade Group?

3 Wall Street analysts have set twelve-month price targets for Trxade Group in the last year. Their average twelve-month price target is $12.33, suggesting a possible upside of 158.6%. National Securities has the highest price target set, predicting MEDS will reach $15.00 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $10.00 for Trxade Group in the next year.
View the latest price targets for MEDS.

What is the current consensus analyst rating for Trxade Group?

Trxade Group currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEDS will outperform the market and that investors should add to their positions of Trxade Group.
View the latest ratings for MEDS.

What other companies compete with Trxade Group?

Other companies that are similar to Trxade Group include Bioasis Technologies, Medizone International, China Medicine, ScripsAmerica and China BCT Pharmacy Group.

How do I contact Trxade Group's investor relations team?

Trxade Group's physical mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The company's listed phone number is 800-261-0281 and its investor relations email address is [email protected] The official website for Trxade Group is www.trxade.com.